State Street Corp Has $72.59 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

State Street Corp lifted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 4.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,770,826 shares of the company’s stock after purchasing an additional 148,491 shares during the period. State Street Corp’s holdings in Syndax Pharmaceuticals were worth $72,588,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $27,000. Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $30,000. nVerses Capital LLC acquired a new position in shares of Syndax Pharmaceuticals during the second quarter valued at $33,000. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals in the third quarter valued at about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the period.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $13.63 on Wednesday. The company has a market capitalization of $1.16 billion, a P/E ratio of -3.76 and a beta of 0.86. The business has a 50-day moving average of $17.72 and a two-hundred day moving average of $19.42. Syndax Pharmaceuticals, Inc. has a 1 year low of $13.26 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the company posted ($0.73) earnings per share. On average, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on SNDX shares. JPMorgan Chase & Co. upped their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 21st. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price for the company. The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Stifel Nicolaus lifted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).